Novel Agents in CNS Myeloma Treatment

Title:Novel Agents in CNS Myeloma Treatment

Volume: 14 Issue: 1

Author(s): Alessandro Gozzetti and Alfonso Cerase

Affiliation:

Keywords: Bortezomib, chemotherapy, CNS, extramedullary myeloma, IMID’s, new agents.

Abstract: Central nervous system localization of multiple myeloma (CNS-MM) accounts for about 1% of all MM. Treatment is still unsatisfactory. Many treatments have been described in the literature: chemotherapy (CHT), intrathecal therapy (IT), and radiotherapy (RT), with survivals reported between one month and six months. Recent drugs such as the immunomodulatory drugs (IMiDs) and proteasome inhibitors (bortezomib) have changed the treatment of patients with MM, both younger and older, with a significant improvement in response and survival. The activity of new drugs in CNSMM has been reported but is still not well known. Bortezomib does not cross the blood brain barrier (BBB), and IMID’s seem to have only a minimal crossover. The role of novel agents in CNS MM management will be discussed as well as the potential role of other new immunomodulatory drugs (pomalidomide) and proteasome inhibitors that seem to cross the BBB and hold promise into the treatment of this rare and still incurable localization of the disease.

Cite this article as:

Gozzetti Alessandro and Cerase Alfonso, Novel Agents in CNS Myeloma Treatment, Central Nervous System Agents in Medicinal Chemistry 2014; 14 (1) . https://dx.doi.org/10.2174/1871524914999140818111514